Skip to main content
Erschienen in: Advances in Therapy 8/2017

13.07.2017 | Review

Intragastric Balloon Treatment for Obesity: Review of Recent Studies

verfasst von: Chinara M. Tate, Allan Geliebter

Erschienen in: Advances in Therapy | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The FDA recently approved three intragastric balloon (IGB) devices, ReShape, ORBERA™, and Obalon for treatment of obesity. Given the high cost, complication risk, and invasiveness of bariatric surgery, IGB treatment may present a safer and lower cost option for weight reduction. IGBs are generally placed in the stomach endoscopically for up to 6 months to reduce gastric capacity, enhance feelings of fullness, and induce weight loss. The mechanism of action likely involves stimulation of gastric mechanoreceptors triggering short-acting vagal signals to brain regions implicated in satiety. Balloon efficacy may be influenced by balloon volume, patient gastric capacity, and treatment duration.

Methods

This review focused on eight recent (2006–present) randomized controlled trials (RCTs) comparing percentage total body weight loss (%TBWL) between IGB and control groups including three reviewed by the FDA. %TBWL based on the reviewed studies was also compared with bariatric surgery and pharmacotherapy.

Results

Of the eight IGB studies, five had balloon treatment duration of 6 months. Efficacy at 6 months, based on a pooled weighted-mean %TBWL, was 9.7%, and the control-subtracted %TBWL was 5.6%. When one study without SDs was removed, the weighted mean %TBWL was 9.3 ± 5.7% SD, and control-subtracted %TBWL was 5.5 ± 7.8%, which was statistically greater than controls. IGB showed lower efficacy than bariatric surgery (median weight loss of 27% for Rouen-Y gastric bypass (RYGB). The control-subtracted %TBWL over 6 months of 5.5–5.6% is less than the most efficacious FDA-approved weight loss drug, Qsymia. At the recommended dose, Qsymia has a placebo-subtracted %TBWL at 6 months of approximately 6.6%. The weighted mean reported incidence of serious adverse events (SAEs) in the IGB group across all eight studies was 10.5%. Only six of the eight reviewed studies reported adverse events (AEs) in the IGB group, with a pooled reported incidence of 28.2%. Recently, the FDA reported new AEs including acute pancreatitis with ReShape and ORBERA™.

Conclusion

Based on the available evidence, it is unlikely that IGB use will supplant other forms of obesity treatment. The estimated cost of endoscopic balloon implantation and retrieval is US $8,150. Collectively, a relatively small control-subtracted %TBWL and the potential for serious complications makes IGB unlikely to become widely adopted. Given the recent FDA warning, IGB longevity on the market is questionable.
Literatur
3.
Zurück zum Zitat Fernandes M, Atallah AN, Soares BGO, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931. Fernandes M, Atallah AN, Soares BGO, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931.
4.
Zurück zum Zitat Benjamin SB, Boyle TM, Agus SG, et al. Small bowel obstruction and the Garren-Edwards® gastric bubble: an iatrogenic bezoar. Gastrointest Endosc. 1988;34(6):463–7.CrossRefPubMed Benjamin SB, Boyle TM, Agus SG, et al. Small bowel obstruction and the Garren-Edwards® gastric bubble: an iatrogenic bezoar. Gastrointest Endosc. 1988;34(6):463–7.CrossRefPubMed
5.
Zurück zum Zitat Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989;35(5):381–5.CrossRefPubMed Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989;35(5):381–5.CrossRefPubMed
6.
Zurück zum Zitat Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Gastrointest Endosc. 1987;33(4):323–7.CrossRefPubMed Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Gastrointest Endosc. 1987;33(4):323–7.CrossRefPubMed
8.
Zurück zum Zitat Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRefPubMed Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRefPubMed
9.
Zurück zum Zitat Apollo Endosurgery Inc. ORBERA ™ intragastric balloon system (ORBERA ™). San Diego: Apollo Endosurgery; 2015. pp. 1–30. Apollo Endosurgery Inc. ORBERA ™ intragastric balloon system (ORBERA ™). San Diego: Apollo Endosurgery; 2015. pp. 1–30.
11.
Zurück zum Zitat Zheng Y, Wang M, He S, Ji G. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med. 2015;13:246. Zheng Y, Wang M, He S, Ji G. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med. 2015;13:246.
12.
Zurück zum Zitat Moura D, Oliveira J, De Moura EGH, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9. Moura D, Oliveira J, De Moura EGH, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9.
13.
Zurück zum Zitat Gaur S, Levy S, Mathus-Vliegen L, Chuttani R. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015;81(6):1330–6.CrossRefPubMed Gaur S, Levy S, Mathus-Vliegen L, Chuttani R. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015;81(6):1330–6.CrossRefPubMed
14.
Zurück zum Zitat Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. Mass Med Soc. 2009. doi:10.1056/NEJMoa0804748. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. Mass Med Soc. 2009. doi:10.​1056/​NEJMoa0804748.
15.
Zurück zum Zitat Genco A, Maselli R, Casella G, Cipriano M, Redler A. Intragastric balloon treatment for obesity. In: Obesity, bariatric and metabolic surgery. Cham: Springer International Publishing; 2016. pp. 485–92. doi:10.1007/978-3-319-04343-2_50. Genco A, Maselli R, Casella G, Cipriano M, Redler A. Intragastric balloon treatment for obesity. In: Obesity, bariatric and metabolic surgery. Cham: Springer International Publishing; 2016. pp. 485–92. doi:10.​1007/​978-3-319-04343-2_​50.
16.
Zurück zum Zitat Karmali S, Birch DW, Sharma AM. Is it time to abandon excess weight loss in reporting surgical weight loss? Surg Obes Relat Dis. 2009;5(4):503–6.CrossRefPubMed Karmali S, Birch DW, Sharma AM. Is it time to abandon excess weight loss in reporting surgical weight loss? Surg Obes Relat Dis. 2009;5(4):503–6.CrossRefPubMed
17.
Zurück zum Zitat Mohammed M. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res. 2014;1:1–5. Mohammed M. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res. 2014;1:1–5.
19.
Zurück zum Zitat Abu Dayyeh BK, Eaton LL, Woodman G, et al. 144 A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subject. Gastrointest Endosc. 2015;81(5):AB147.CrossRef Abu Dayyeh BK, Eaton LL, Woodman G, et al. 144 A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subject. Gastrointest Endosc. 2015;81(5):AB147.CrossRef
21.
Zurück zum Zitat Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity. 2013;21(8):1561–70. doi:10.1002/oby.20414.CrossRefPubMed Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity. 2013;21(8):1561–70. doi:10.​1002/​oby.​20414.CrossRefPubMed
22.
Zurück zum Zitat Higgins JPT, Green SE, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2011. Higgins JPT, Green SE, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2011.
23.
Zurück zum Zitat Genco A, Cipriano M, Bacci V, et al. BioEnterics® Intragastric Balloon (BIB®): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33. doi:10.1038/sj.ijo.0803094.CrossRef Genco A, Cipriano M, Bacci V, et al. BioEnterics® Intragastric Balloon (BIB®): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33. doi:10.​1038/​sj.​ijo.​0803094.CrossRef
24.
Zurück zum Zitat Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57. Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.
25.
Zurück zum Zitat Courcoulas A, Dayyeh BA, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427–33. Courcoulas A, Dayyeh BA, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427–33.
27.
Zurück zum Zitat Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170–80.CrossRefPubMed Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170–80.CrossRefPubMed
28.
Zurück zum Zitat Chang S-H, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149(3):275–87. Chang S-H, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149(3):275–87.
30.
Zurück zum Zitat Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc. 2017;85(5):936.e3–44.e3.CrossRef Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc. 2017;85(5):936.e3–44.e3.CrossRef
31.
Zurück zum Zitat Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425.e5–38.e5.CrossRef Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425.e5–38.e5.CrossRef
32.
Zurück zum Zitat Robinson OG, Benos DJ, Mazzochi C. Spontaneous autoinflation of saline mammary implants: further studies. Aesthetic Surg J. 2005;25(6):582–6.CrossRef Robinson OG, Benos DJ, Mazzochi C. Spontaneous autoinflation of saline mammary implants: further studies. Aesthetic Surg J. 2005;25(6):582–6.CrossRef
33.
Zurück zum Zitat Seng P, Bayle S, Alliez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis. 2015;35:62–6.CrossRefPubMed Seng P, Bayle S, Alliez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis. 2015;35:62–6.CrossRefPubMed
34.
Zurück zum Zitat Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014;1:36. Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014;1:36.
37.
Zurück zum Zitat Cho Y-S, Kim H-K, Jang E-C, et al. Usefulness of the bedside index for severity in acute pancreatitis in the early prediction of severity and mortality in acute pancreatitis. Pancreas. 2013;42(3):483–7. Cho Y-S, Kim H-K, Jang E-C, et al. Usefulness of the bedside index for severity in acute pancreatitis in the early prediction of severity and mortality in acute pancreatitis. Pancreas. 2013;42(3):483–7.
38.
Zurück zum Zitat Ozaki N, Sengupta JN, Gebhart GF, et al. Mechanosensitive properties of gastric vagal afferent fibers in the rat. J Neurophysiol. 1999;82(5):2210–20. Ozaki N, Sengupta JN, Gebhart GF, et al. Mechanosensitive properties of gastric vagal afferent fibers in the rat. J Neurophysiol. 1999;82(5):2210–20.
41.
Zurück zum Zitat Wang G-J, Tomasi D, Backus W, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 2008;39(4):1824–31.CrossRefPubMed Wang G-J, Tomasi D, Backus W, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 2008;39(4):1824–31.CrossRefPubMed
42.
Zurück zum Zitat Geliebter A, Westreich S, Gage D. Gastric distension by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr. 1988;48(3):592–4.PubMed Geliebter A, Westreich S, Gage D. Gastric distension by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr. 1988;48(3):592–4.PubMed
43.
Zurück zum Zitat Geliebter A, Melton PM, Gage D, McCray RS, Hashim SA. Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr. 1990;51(4):584–8. Geliebter A, Melton PM, Gage D, McCray RS, Hashim SA. Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr. 1990;51(4):584–8.
44.
Zurück zum Zitat Granström L, Backman L. Stomach distension in extremely obese and in normal subjects. Acta Chir Scand. 1985;151(4):367–70. Granström L, Backman L. Stomach distension in extremely obese and in normal subjects. Acta Chir Scand. 1985;151(4):367–70.
45.
Zurück zum Zitat Geliebter A, Westreich S, Gage D, Hashim SA. Intragastric balloon reduces food intake and body weight in rats. Am J Physiol. 1986;251(2):R794–7.PubMed Geliebter A, Westreich S, Gage D, Hashim SA. Intragastric balloon reduces food intake and body weight in rats. Am J Physiol. 1986;251(2):R794–7.PubMed
46.
Zurück zum Zitat Geliebter A, Melton PM, McCray RS, et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes. 1991;15(4):259–66.PubMed Geliebter A, Melton PM, McCray RS, et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes. 1991;15(4):259–66.PubMed
47.
Zurück zum Zitat Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.CrossRefPubMed Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.CrossRefPubMed
48.
Zurück zum Zitat Shelby VS, James MS, George W, Steven E, Tarek I, Shayani H. The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. In: Digestive disease week. San Diego; 2016. http://www.ddw.org/program/online-planner. Shelby VS, James MS, George W, Steven E, Tarek I, Shayani H. The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. In: Digestive disease week. San Diego; 2016. http://​www.​ddw.​org/​program/​online-planner.
49.
Zurück zum Zitat Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg. 2013;23(5):730–3. Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg. 2013;23(5):730–3.
50.
Zurück zum Zitat Nobili V, Corte CD, Liccardo D, et al. Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study. Pediatr Obes. 2015;10(5):e1–4.CrossRefPubMed Nobili V, Corte CD, Liccardo D, et al. Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study. Pediatr Obes. 2015;10(5):e1–4.CrossRefPubMed
51.
Zurück zum Zitat Machytka E, Chuttani R, Bojkova M, et al. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26:512–6.CrossRefPubMed Machytka E, Chuttani R, Bojkova M, et al. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26:512–6.CrossRefPubMed
53.
Zurück zum Zitat Galanti K, Gluck ME, Geliebter A. Test meal intake in obese binge eaters in relation to impulsivity and compulsivity. Int J Eat Disord. 2007;40(8):727–32.CrossRefPubMed Galanti K, Gluck ME, Geliebter A. Test meal intake in obese binge eaters in relation to impulsivity and compulsivity. Int J Eat Disord. 2007;40(8):727–32.CrossRefPubMed
54.
Zurück zum Zitat Geliebter A, Yahav E, Gluck M, Hashim S. Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder. Physiol Behav. 2004;81(5):735–40. Geliebter A, Yahav E, Gluck M, Hashim S. Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder. Physiol Behav. 2004;81(5):735–40.
Metadaten
Titel
Intragastric Balloon Treatment for Obesity: Review of Recent Studies
verfasst von
Chinara M. Tate
Allan Geliebter
Publikationsdatum
13.07.2017
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 8/2017
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0562-3

Weitere Artikel der Ausgabe 8/2017

Advances in Therapy 8/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.